Teclison
Teclison is a biotech company. It has raised $5.9M across 1 round, most recently a $5.9M Series A in February 2022.
Transforming cancer treatment by enhancing immunotherapy
- Website
- teclison.com
- Total Funding
- $5.9M
- Last Round
- $5.9M Series AFeb 2022
- Rounds
- 1
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
Indexed holds 1 funding round and 1 investor for this company. The full record is or through the API.
About
Teclison develops cancer therapies designed to induce tumor necrosis and enhance antitumor immunity. Its platform aims to remodel the tumor immune microenvironment of solid cancers to help patients who respond poorly to existing immunotherapies. Its pipeline approaches seek to enhance immune checkpoint inhibitors and prolong the lives of patients whose solid tumor cancers have metastasized to the liver.
Summary
It has raised $5.9M in total across 1 round, most recently a $5.9M Series A round in Feb 2022. Investors include WTT Investment.
Tech & App Stack
2 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Feb 2022
Investors
Similar Companies
China's leading blood products manufacturer

One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract research organization providing comprehensive drug development and laboratory ser...

Specialty pharmaceutical company
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/teclison"><img src="https://indexed.vc/api/badge/company/teclison" alt="Teclison on Indexed.vc" width="260" height="76" /></a>